Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 ENFERMEDAD GRUPO REGISTRY PROYECTOS ENTRAR
 
 
  
EHDN2012 - Documents - Presentations -
--->Novedades
[-]El proyecto
--->Sponsor
--->[+]Comité Ejecutivo
--->[+]Writing Committee Strategic ...
--->[+]Comité Científico y Bioético
--->Coordinador central
--->Coordinadores locales
--->Fellowship Programme
--->[+]Constitución
--->[+]Elecciones
--->[-]Miembros
--->Solicitud
[-]Centros
--->[+]Austria
--->[+]Bélgica
--->[+]República Checa
--->[+]Dinamarca
--->[+]Finlandia
--->[+]Francia
--->[+]Alemania
--->[+]Ireland
--->[+]Italia
--->[+]Países Bajos
--->[+]Noruega
--->[+]Polonia
--->[+]Portugal
--->[+]Rusia
--->[+]España
--->[+]Suecia
--->[+]Suiza
--->[+]Reino Unido
--->[-]Fuera de Europa
--->[-]Seoul
--->Contacts
--->[+]Singapore
--->Sydney
[+]Grupos de trabajo
[-]Eventos
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[+]Posters
--->Contacts
--->Feedback & Evaluation
--->[-]EHDN 2010
--->Introduction
--->Programme I
--->Programme II
--->Additional Meetings
--->Registration
--->EHA Programme
--->[+]EHA Registration
--->Plenary Dinner
--->Social Programme
--->Important Dates
--->[+]Abstract Submission
--->Reimbursement
--->Hotel Booking
--->[+]Travel and Location
--->[+]About Prague
--->Documents
--->Committees
--->Contact
--->Feedback & Evaluation
--->[-]EHDN 2008
--->Programa
--->Otras reuniones
--->Programa de la AHE
--->Programa social
--->Programa infantil
--->Fechas a recordar
--->Voting
--->Reembolso
--->[+]Inscripción
--->[+]Submisión de abstracts
--->Evaluation & Feedback
--->[+]Viaje y alojamiento
--->[+]Lisboa
--->[+]Documentos
--->Comités
--->Contacto
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[+]Comunicación
--->Ofertas de trabajo
fechadescripcióntamañoautor documento 
04.05.26Stem cells for basic research on HD32 kBanonymousapplication/mswordehdn-2012-ellerby 
04.05.26Stem cells for basic research on HD32 kBanonymousapplication/mswordehdn-2012-l-thompson-empty-file 
04.05.26Keynote presentations32 kBanonymousapplication/mswordehdn-2012-aronin-empty-file 
04.05.26Post-translational modifications of huntingtin32 kBanonymousapplication/mswordehdn-2012-saudou-empty-file 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-quarrell-empty-file 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-craufurd-empty-file 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-reilmann-empty-file 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-j-thompson-empty-file 
04.05.26Updates on lowering huntingtin (htt) levels32 kBanonymousapplication/mswordehdn-2012-davidson-empty-file 
04.05.26HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplasmic aggregation and rescues synaptic dysfunction in HD mouse models32 kBanonymousapplication/mswordehdn-2012-bates-empty-file 
04.05.26Sirt1-inhibition: SienaBiotech32 kBanonymousapplication/mswordehdn-2012-caricasole-empty-file 
04.05.26PDE-10-inhibition: Pfizer32 kBanonymousapplication/mswordehdn-2012-schmidt-empty-file 
04.05.26PDE-4-inhibition: GSK32 kBanonymousapplication/mswordehdn-2012-gray-empty-file 
04.05.26Htt lowering: Medtronic-Alnylam/Isis/CHDI32 kBanonymousapplication/mswordehdn-2012-mcdonald-empty-file 
04.05.26Phenotyping neural networks in an ovine model of HD32 kBanonymousapplication/mswordehdn-2012-perentos-empty-file 
04.05.26Aging pathway and poly-Q neurotoxicity32 kBanonymousapplication/mswordehdn-2012-nollen 
04.05.26NeuroNet and its potential for the study of neurodegeneration32 kBanonymousapplication/mswordehdn-2012-wanker-empty-file 
04.05.26Behavioral assessment and management of behavioral issues32 kBanonymousapplication/mswordehdn-2012-anderson-empty-file 
04.05.26Differential diagnosis of chorea32 kBanonymousapplication/mswordehdn-2012-walker-empty-file 
04.05.26Post-translational modifications and proteolysis of huntingtin32 kBanonymousapplication/mswordehdn-2012-truant-empty-file 
04.05.26Advanced HD Working Group32 kBanonymousapplication/mswordehdn-2012-youssov-empty-file 
04.05.26Animal studies on the effects of physiotherapy32 kBanonymousapplication/mswordehdn-2012-brooks-empty-file 
04.05.26RNA toxicity in poly-Q disorders32 kBanonymousapplication/mswordehdn-2012-krzyzosiak 
04.05.26Longevity pathways and their relevance to human disease32 kBanonymousapplication/mswordehdn-2012--aguilaniu-empty-file 
04.05.26Frequency of Huntington Disease - Greater than you think32 kBanonymousapplication/mswordehdn-2012-hayden-empty-file 
04.05.26What are we really looking for in an HD drug?32 kBanonymousapplication/mswordehdn-2012-sampaio-empty-file 
04.05.26Care, coping and research in HD – the earlier the better!32 kBanonymousapplication/mswordehdn-2012-duerr-empty-file 
04.05.26Human physiotherapy studies32 kBanonymousapplication/mswordehdn-2012-busse-empty-file 
04.05.26Default-mode network changes in preclinical Huntington´s disease32 kBanonymousapplication/mswordehdn-2012-orth-empty-file 
04.05.26Cognitive alterations in HD32 kBanonymousapplication/mswordehdn-2012-stout-empty-file 
04.05.26Lessons of the day32 kBanonymousapplication/mswordehdn-2012-wild-empty-file 
04.05.26Clinical management of Huntington’s disease32 kBanonymousapplication/mswordehdn-2012-nance-empty-file 
04.05.26Update on stem cell research: clinical potentials32 kBanonymousapplication/mswordehdn-2012-brundin-empty-file 
04.05.26Critical consideration of the criteria for the motor diagnosis of HD32 kBanonymousapplication/mswordehdn-2012-paulsen-empty-file 
04.05.26Longitudinal functional and connectivity changes during working memory performance in HD32 kBanonymousapplication/mswordehdn-2012-georgiou-karistianis-empty-f... 
04.05.26Better global and cognitive functioning for choreatic compared to hypokinetic- rigid HD32 kBanonymousapplication/mswordehdn-2012-t-hart-empty-file 
04.05.26Bupropion: ACTION-HD32 kBanonymousapplication/mswordehdn-2012-priller-empty-file 
04.05.26Overview of CHDI drug development programs32 kBanonymousapplication/mswordehdn-2012-pacifici 
04.05.26Drug discovery and development process32 kBanonymousapplication/mswordehdn-2012-kwak-empty-file 
04.05.26Lessons of the day32 kBanonymousapplication/mswordehdn-2012-wild-empty-file 
04.05.26Standards of Care32 kBanonymousapplication/mswordehdn-2012-rea-empty-file 
04.05.26EHDN Update - EC elections, SBAC elections, Structure of EHDN32 kBanonymousapplication/mswordehdn-2012-landwehrmeyer-empty-file 
04.05.26Dopaminergic stabilization in HD: pridopidine32 kBanonymousapplication/mswordehdn-2012-kieburtz-empty-file 
04.05.26Reach2HD PBT232 kBanonymousapplication/mswordehdn-2012-stout-empty-file 
04.05.26PREQUEL EHDN32 kBanonymousapplication/mswordehdn-2012-ross-empty-file 
04.05.26Juvenile Huntington's disease32 kBanonymousapplication/msworda03-juvenile-hd 
04.05.26Default-mode network changes in preclinical Huntington’s disease32 kBanonymousapplication/msworda04-default-mode-network-changes 
04.05.26New assessment tools (cognitive batteries)32 kBanonymousapplication/mswordehdn-2012-stout-empty-file 
04.05.26Poster Awards32 kBanonymousapplication/mswordehdn-2012-landwehrmeyer-empty-file 
04.05.26REGISTRY and Enroll-HD32 kBanonymousapplication/mswordehdn-2012-landwehrmeyer-empty-file 
04.05.26Better global and cognitive functioning for choreatic compared to hypokinetic-rigid Huntington’s disease32 kBanonymousapplication/msworda06-better-global-and-cognitive-functi... 
04.05.26Progress in HD research and HD advocacy: a personal view32 kBanonymousapplication/mswordehdn-2012-sabine-empty-file 
04.05.26Juvenile HD Working Group32 kBanonymousapplication/mswordehdn-2012-quarrell 
04.05.26MRI as a potential marker for HD32 kBanonymousapplication/mswordehdn-2012-scahill 
04.05.26Defining predictors of disease32 kBanonymousapplication/msworda11-induced-pluripotent-stem-cells 
04.05.26Presentation of the HDYO website32 kBanonymousapplication/mswordehdn-2012-ellison 
04.05.26Huntingtin32 kBanonymousapplication/mswordehdn-2012-cattaneo 
04.05.26Falling in love, staying in love32 kBanonymousapplication/mswordeha-2012-mol 
04.05.26Defining predictors of disease32 kBanonymousapplication/mswordehdn-2012-tabrizi 
04.05.26Critical consideration of the criteria for the motor diagnosis of Huntington disease32 kBanonymousapplication/msworda07-critical-consideration-criteria-mo... 
04.05.26New assessment tools (cognitive batteries)32 kBanonymousapplication/mswordehdn-2012-bachoud-levi-empty-file 
04.05.26Brain imaging as a potential marker for HD (PET)32 kBanonymousapplication/mswordehdn-2012-varrone-empty-file 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-reilmann-empty-file 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-craufurd-empty-file 
04.05.26Scientific strategy of EHDN32 kBanonymousapplication/mswordehdn-2012-bronzova 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-quarrell-empty-file 
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/mswordehdn-2012-thompson-empty-file 
04.05.26Common issues/problems/inconsistencies in HD assessments32 kBanonymousapplication/mswordehdn-2012-ferreira-empty-file 
04.05.26HD for Basic Scientists32 kBanonymousapplication/mswordehdn-2012-landwehrmeyer-empty-file 
11.04.13Plenary Session I: ‘A look ahead’33blankintext/x-cms-notePlenary-Session-I 
11.04.13Plenary Session II: ‘Frontiers in biology and their relevance to Huntington’s disease’ 33blankintext/x-cms-notePlenary-Session-II 
11.04.13Plenary Session III: ‘Science practice at EHDN’ 33blankintext/x-cms-notePlenary-Session-III 
11.04.13Short Communications I: 'Scientific Presentations: 10’ and 5’ questions – selected from submissions' 33blankintext/x-cms-noteShort-Communications-I 
11.04.13Plenary Session IV: Keynote presentations33blankintext/x-cms-notePlenary-Session-IV 
11.04.13Roundup I33blankintext/x-cms-noteRoundup-I 
11.04.13Breakfast teaching courses Sat33blankintext/x-cms-noteBreakfast-teaching-courses-sat 
11.04.13Plenary Session V: ‘Understanding and manipulating the pathogenic process in Huntington’s disease’ 33blankintext/x-cms-notePlenary-Session-V 
11.04.13Plenary Session VI: Keynote presentations33blankintext/x-cms-notePlenary-Session-VI 
11.04.13Short communications II: Scientific presentations33blankintext/x-cms-noteShort-communications-II 
11.04.13Plenary Session VII: ‘Therapeutic development programs in Huntington’s Disease’33blankintext/x-cms-notePlenary-Session-VII 
08.04.13Plenary Session VIII: EHDN Business Meeting33blankintext/x-cms-notePlenary-Session-VIII 
08.04.13Roundup II33blankintext/x-cms-noteRoundup-II 
08.04.13Breakfast teaching courses Sun33blankintext/x-cms-noteBreakfast-teaching-courses-sun 
08.04.13Plenary Session IX: ‘Tools and outcome to monitor disease progression and response to therapy’33blankintext/x-cms-notePlenary-Session-IX 
08.04.13Roundup III33blankintext/x-cms-noteRoundup-III 
08.04.13EHA meeting33blankintext/x-cms-noteEHA-meeting 
08.04.13Oral Presentations33blankintext/x-cms-noteOral-Presentations 

Esta carpeta contiene 87 documentos.
about us | privacy statement | disclaimer | terms of use